New State-by-State PrEP-Use Map from AIDSVu
AIDSVu recently released the first-ever, interactive, state-level maps summarizing trends in the use of PrEP across the U.S. According to the data, PrEP use increased at an average rate of about 73% annually during the period from 2012 through 2016, rising to a total of more than 77,000 PrEP users nationwide by 2016. The AIDSVu site provides interactive maps illustrating HIV prevalence, new HIV diagnoses, and mortality – and now PrEP use – across the United States. AIDSVu is a project of Emory University’s Rollins School of Public Health in partnership with Gilead Sciences and the Center for AIDS Research (CFAR) at Emory. Selected highlights of PrEP data on the AIDSVu site are summarized below. Please note that, unless otherwise indicated, the data presented are for 2016 – the latest year for which detailed data are available.
- the number of PrEP users increased 880% between 2012 and 2016, rising from about 8,768 users to 77,120 users during the period;
- 93% of all PrEP users were male, and 7% were female;
- nearly half of all PrEP users were located in just five states: New York, California, Florida, Texas, and Illinois;
- the highest rates of PrEP use – as measured by the number of persons using PrEP per 100,000 population – were in New York, Massachusetts, Rhode Island, Washington, and Illinois; and
- the Northeast region had the highest rate of PrEP use per 100,000 population (47.4) – approximately double that in the West (28.1), the Midwest (23.5), and the South (22.6).
To mark the launch of its PrEP maps, the AIDSVu blog posted several recent interviews in which HIV experts discuss PrEP usage trends, access, and gender disparities in question-and-answer format.
Public Health Service Updates Its Clinical Practice Guidelines for PrEP
The U.S. Public Health Service (PHS) recently published updated Clinical Practice Guidelines on the use of PrEP for HIV prevention in the United States. The revised guidelines include new data on the safety and efficacy of PrEP, indications for PrEP use, laboratory tests and diagnostic procedures, and considerations – such as potential drug interactions – when providing PrEP to persons at risk for HIV infection. PHS notes that recent updates to the guidelines are highlighted in yellow throughout the document and “are intended solely to update the developing evidence base or to clarify specific points in clinical care. No changes were made to the graded recommendations for the use of PrEP in the U.S.”